Discover published sets by community

Drug class: Atypical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Antagonist at dopamine D2 and serotonin 5-HT2A receptors.

Drug class: Mood stabilizer, Primary indication: Bipolar disorder, Mechanism of action: Modulates neurotransmitter release and affects neuronal excitability.

Drug class: Benzodiazepine, Primary indication: Panic disorder, Mechanism of action: Enhances the GABA neurotransmitter, producing a calming effect.

Drug class: Atypical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Partial agonist at dopamine D2 and serotonin 5-HT1A receptors, antagonist at 5-HT2A.

Drug class: Tetracyclic antidepressant, Primary indication: Major depressive disorder, Mechanism of action: Antagonist at central presynaptic alpha-2 adrenergic inhibitors which increases release of norepinephrine and serotonin.

Drug class: Selective Serotonin Reuptake Inhibitor (SSRI), Primary indication: Major depressive disorder, Mechanism of action: Inhibits the reuptake of serotonin in the brain.

Drug class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Primary indication: Major depressive disorder, Mechanism of action: Inhibits the reuptake of serotonin and norepinephrine.

Drug class: Atypical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Antagonist at D2, 5-HT2A, and multiple other receptors.

Drug class: Stimulant, Primary indication: Attention-Deficit/Hyperactivity Disorder (ADHD), Mechanism of action: Increases the release of norepinephrine and dopamine.

Drug class: Benzodiazepine, Primary indication: Anxiety disorders, Mechanism of action: Enhances the GABA neurotransmitter, producing a calming effect on the brain.

Drug class: Atypical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Antagonist at multiple neurotransmitter receptors including D2, 5-HT2A.

Drug class: Anticonvulsant/Mood stabilizer, Primary indication: Bipolar disorder, Mechanism of action: Increases GABA in the brain and may also inhibit sodium channels.

Drug class: Selective Serotonin Reuptake Inhibitor (SSRI), Primary indication: Major depressive disorder, Mechanism of action: Inhibits the reuptake of serotonin in the brain.

Drug class: Atypical antipsychotic, Primary indication: Treatment-resistant schizophrenia, Mechanism of action: Binds to multiple neurotransmitter receptors, including D2, 5-HT2A, 5-HT2C.

Drug class: Norepinephrine-Dopamine Reuptake Inhibitor (NDRI), Primary indication: Major depressive disorder, Mechanism of action: Inhibits the reuptake of norepinephrine and dopamine.

Drug class: Atypical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Antagonist at D2 and 5-HT2A receptors, and agonist at 5-HT1A receptors.

Drug class: Anticonvulsant/Mood stabilizer, Primary indication: Bipolar disorder, Mechanism of action: Blocks sodium channels, which inhibits rapid firing of neurons.

Drug class: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Primary indication: Major depressive disorder, Mechanism of action: Inhibits the reuptake of serotonin and norepinephrine in the brain.

Drug class: Typical antipsychotic, Primary indication: Schizophrenia, Mechanism of action: Antagonist at D2 dopamine receptors.